Payer Coverage

Coherus COMPLETE™ Payer
Coverage TOOL

UDENYCA^{^®} (pegfilgrastim-cbqv)

Coverage Announcements

As payers make coverage policy changes and announcements regarding UDENYCA^{^®}, you can stay informed by checking the announcements below.

February 2021

Aetna has designated UDENYCA^® and the reference product as co-preferred pegfilgrastims under the Commercial Medical Benefit.
Read more: Hematopoietic Colony-Stimulating Factors (CSFs) - Medical Clinical Policy Bulletins | Aetna.
February 2021

Anthem has designated UDENYCA^® and the reference product as co-preferred pegfilgrastims covered under the Commercial and Medicare Medical Benefit.
Read more: Anthem Clinical Criteria: Colony Stimulating Factor Agents.
January 2021

TRICARE^® has designated UDENYCA^® as a preferred pegfilgrastim and available without a prior authorization (PA).
Read more: TRICARE Formulary Search
January 2021

UnitedHealthcare and Optum have designated UDENYCA^® the co-preferred pegfilgrastim for Medicare Advantage.
Read more: UnitedHealthcare^® Medicare Advantage Policy Guideline: Colony Stimulating Factors
January 2021

Blue Shield of California has designated UDENYCA^®, the reference product, and pegfilgrastim-bmez as preferred pegfilgrastims covered under the Commercial Medical Benefit.
September 2020

Independent Health Medicare Policies has updated UDENYCA^® to be the Preferred Agent with the reference product
August 2020

Select Health has updated UDENYCA^® to be the Preferred Agent with pegfilgrastim-jmdb
Read more: Select Health has updated UDENYCA^® (pegfilgrastim-cbqv) to be the Preferred Agent with Fulphila^® (pegfilgrastim-jmdb)
June 2020

Florida Medicaid has updated UDENYCA^® to be the Preferred Agent
Read more: Florida Medicaid has updated UDENYCA^® (pegfilgrastim-cbqv) to be the Preferred Agent
May 2020

Minnesota Medicaid has updated UDENYCA^® to be the Preferred Agent with all other pegfilgrastim biosimilars
Read more: Minnesota Medicaid has updated UDENYCA^® (pegfilgrastim-cbqv) to be the Preferred Agent with all other pegfilgrastim biosimilars
March 2020

BCBS Vermont has updated UDENYCA^® to be the Preferred Agent with pegfilgrastim-bmez
March 2020

Select Health has updated UDENYCA^® to be the Preferred Agent with the reference product.
Read More: Select Health has updated UDENYCA^® to be the Preferred Agent with Neulasta^®
January 2020

Ventegra has updated UDENYCA^® to be the Preferred Pegfilgrastim on their Formulary.
Read More: Ventegra has updated UDENYCA^® to be the Preferred Pegfilgrastim on their Formulary
January 2020

Express Scripts has updated UDENYCA^® to be the Preferred Agent with the reference product in the National & Basic Formulary List.
Read More: Express Scripts has updated UDENYCA^® to be the Preferred Agent with Neulasta^®
April 2019

UDENYCA^® assigned transitional pass-through status April 1, 2019.
Read More: April 2019 Update of the Hospital OPPS
April 2019

UDENYCA^® added to BuyandBill.com.
Read More: Buyandbill.com UDENYCA^®
March 2019

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Hematopoietic Growth Factors Updated to include pegfilgrastim-cbqv*
Read More: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Hematopoietic Growth Factors Updated to include Pegfilgrastim-cbqv

* Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Hematopoietic Growth Factors V.2.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed July 13, 2020. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Contact Us

1-844-4-UDENYCA
(1-844-483-3692)
Fax 1-877-226-6370

Coherus.com | UDENYCA.com

Coherus reserves the right to revise or terminate the CoherusCOMPLETE^™ without any notice at any time

UDENYCA® (pegfilgrastim-cbqv)

Coverage Announcements

Aetna has designated UDENYCA® and the reference product as co-preferred pegfilgrastims under the Commercial Medical Benefit.

Anthem has designated UDENYCA® and the reference product as co-preferred pegfilgrastims covered under the Commercial and Medicare Medical Benefit.

TRICARE® has designated UDENYCA® as a preferred pegfilgrastim and available without a prior authorization (PA).

UnitedHealthcare and Optum have designated UDENYCA® the co-preferred pegfilgrastim for Medicare Advantage.

Blue Shield of California has designated UDENYCA®, the reference product, and pegfilgrastim-bmez as preferred pegfilgrastims covered under the Commercial Medical Benefit.

Independent Health Medicare Policies has updated UDENYCA® to be the Preferred Agent with the reference product

Select Health has updated UDENYCA® to be the Preferred Agent with pegfilgrastim-jmdb

Florida Medicaid has updated UDENYCA® to be the Preferred Agent

Minnesota Medicaid has updated UDENYCA® to be the Preferred Agent with all other pegfilgrastim biosimilars

BCBS Vermont has updated UDENYCA® to be the Preferred Agent with pegfilgrastim-bmez

Select Health has updated UDENYCA® to be the Preferred Agent with the reference product.

Ventegra has updated UDENYCA® to be the Preferred Pegfilgrastim on their Formulary.

Express Scripts has updated UDENYCA® to be the Preferred Agent with the reference product in the National & Basic Formulary List.

UDENYCA® assigned transitional pass-through status April 1, 2019.

UDENYCA® added to BuyandBill.com.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Growth Factors Updated to include pegfilgrastim-cbqv*

Contact Us

UDENYCA^{^®} (pegfilgrastim-cbqv)

Aetna has designated UDENYCA^® and the reference product as co-preferred pegfilgrastims under the Commercial Medical Benefit.

Anthem has designated UDENYCA^® and the reference product as co-preferred pegfilgrastims covered under the Commercial and Medicare Medical Benefit.

TRICARE^® has designated UDENYCA^® as a preferred pegfilgrastim and available without a prior authorization (PA).

UnitedHealthcare and Optum have designated UDENYCA^® the co-preferred pegfilgrastim for Medicare Advantage.

Blue Shield of California has designated UDENYCA^®, the reference product, and pegfilgrastim-bmez as preferred pegfilgrastims covered under the Commercial Medical Benefit.

Independent Health Medicare Policies has updated UDENYCA^® to be the Preferred Agent with the reference product

Select Health has updated UDENYCA^® to be the Preferred Agent with pegfilgrastim-jmdb

Florida Medicaid has updated UDENYCA^® to be the Preferred Agent

Minnesota Medicaid has updated UDENYCA^® to be the Preferred Agent with all other pegfilgrastim biosimilars

BCBS Vermont has updated UDENYCA^® to be the Preferred Agent with pegfilgrastim-bmez

Select Health has updated UDENYCA^® to be the Preferred Agent with the reference product.

Ventegra has updated UDENYCA^® to be the Preferred Pegfilgrastim on their Formulary.

Express Scripts has updated UDENYCA^® to be the Preferred Agent with the reference product in the National & Basic Formulary List.

UDENYCA^® assigned transitional pass-through status April 1, 2019.

UDENYCA^® added to BuyandBill.com.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Hematopoietic Growth Factors Updated to include pegfilgrastim-cbqv*